🚨 New Paper Alert! 🚨 Nivolumab plus Cabozantinib Maintains Long-Term Survival Benefit in Advanced Renal Cell Carcinoma

oncodaily.com/55697.html

ESMO Open Tom Powles Andrea Apolo, M.D. Toni Choueiri, MD Maite Bourlon Mauricio Burotto Howard Gurney Elizabeth R Kessler @myesmo Yoshihiko Tomita…

Looking for teams for #uromigoslive24 to take on the team from LA. Hard it beat Tanya, Monty and Petros…..

Brian Rini, MD Uromigos Tom Powles Nazli Dizman Toni Choueiri, MD Neeraj Agarwal, MD, FASCO 💙alison birtle Petros Grivas Rana McKay Tanya Dorff Matt Galsky “Maybe.”

Just out on ESMO Open
By our OncoAlert 🚨GU faculty Tom Powles Andrea Apolo, M.D. Toni Choueiri, MD and Team

Extended Follow Up from CheckMate 9ER

Report provides updated efficacy and safety data on Nivolumab plus Cabozantinib (NIVO + CABO) 🆚 sunitinib (SUN) for 1⃣st line treatment…

Just out in ESMO open ESMO - Eur. Oncology With 44.0 months of median follow-up nivolumab/cabozantinib continues to outperform sunitinib in M1 clear cell RCC. The 3 VEGF/TKI combinations have more similarities than differences and track each other with longer follow up gbr01.safelinks.protection.outlook.com/?url=https%3A%…

Singapore Translational Cancer Consortium & Mount Sinai Hospital joining the IMCORE cancer research collaboration of 27 cancer centres & Roche. 96 cancer research project with >2000 scientists/HCPs and many high impact publications.Asian expansion reflects the global network

The anti–programmed death 1 antibody pembrolizumab was approved by the U.S. FDA as adjuvant therapy after surgery for renal-cell carcinoma on the basis of improvements in disease-free survival observed in KEYNOTE-564. Data on overall survival are needed. nej.md/3TVLuKz

The Uromigos Cup has come home.

#BestCoast Tanya Dorff
#NextStopSeattle Petros Grivas
#WhoWillWinNext #UromigosLive24

Subset data from belzutifan vs everolimus study in pretreated clear cell RCC #IKCS24 . We thought belzutifan would be better in good risk disease and with fewer lines of therapy but these data suggest that’s not the case. Biomakers will need to be biological rather than clinical

Updated data with lenvatinib and Pembrolizumab in 158 1st line advanced non-clear cell renal cancer #ikcs24 . 8 mnths extra FU. RR= 50% seems higher than sunitinib. 18 month mPFS and 80% 12 month OS also looks ⬆️, but randomised trials such as SAMETA and XL92/nivo remain important

1/ The long-awaited OS results from #KEYNOTE -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC .

nejm.org/doi/full/10.10…

Adjuvant pembrolizumab shows a significant and clinically meaningful OS benefit in intermediate and high risk clear cell renal cancer for the 1st time (KN564). This further tips the balance towards giving adjuvant pembro in this setting NEJM Toni Choueiri, MD nejm.org/doi/full/10.10…

ESMO Open (ESMO Open) is among the fastest growing journals in oncology. Consider submitting your data to the Open Access journal of ESMO - Eur. Oncology! journalinsights.elsevier.com/journals/2059-…

Data from the control arm of adjuvant bladder cancer trials (CM274 and Ambassador250) suggests ~35% get no further therapy after relapse (accounting for censoring). Excellent sites. Chemo is globally available. Regular CT follow should catch early & treat. Any easy explanations?

Subsequent treatment of control arm of adjuvant trials is causing controversy due to subsequent IO access. In the +ve renal & bladder studies 81%/48% and ~62%/~36% received further therapy/IO respectively.However the figure below shows these analysis are time dependant & complex

Trial in progress: the HER2/MMAE ADC disitimab Vedotin +pembro vs chemotherapy +\-avelumab in advanced UC(HER2+ve). DVs efficacy looks ⬆️ also with IO. Tox profile looks distinct with ? ⬇️ skin tox? #EAU24 Results will be considered in the context of other +ve 1st line studies

Adjuvant nivo #EAU24 Matt Galsky podcasters.spotify.com/pod/show/the-u…

ctDNA analysis in IM011 screening population #EAU24 Matt Galsky podcasters.spotify.com/pod/show/the-u…

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24